- Phase 3 EPCORE DLBCL-1 trial enrolled 483 patients with relapsed/refractory DLBCL.
- Epcoritamab improved progression-free survival with HR: 0.74.
- Overall survival HR: 0.96 did not reach statistical significance.
- Full trial results to be presented at a future medical meeting.
Trial Overview
The Phase 3 EPCORE DLBCL-1 trial evaluated epcoritamab, a T-cell engaging bispecific antibody, in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study enrolled 483 patients who had at least one prior line of therapy and were ineligible for high-dose chemotherapy and autologous stem cell transplant.
Key Findings
Epcoritamab demonstrated an improvement in progression-free survival (PFS) with a hazard ratio (HR) of 0.74. Improvements were also noted in complete response rate, duration of response, and time to next treatment. However, the overall survival (OS) HR of 0.96 did not reach statistical significance.
Safety and Future Plans
The adverse events observed were consistent with the known safety profile of epcoritamab. Further analysis is ongoing, considering factors like the COVID-19 pandemic and new anti-lymphoma therapies. Full trial results will be presented at a future medical meeting.
Upcoming Trials
Data from two additional Phase 3 trials, EPCORE DLBCL-2 and EPCORE DLBCL-4, are expected in 2026. These trials will evaluate epcoritamab in combination with other treatments for DLBCL.
